RenovoRx (RNXT) Capital Expenditures (2025 - 2026)
RenovoRx (RNXT) posted Capital Expenditures of $2000.0 for Q2 2025.
RenovoRx (RNXT) Capital Expenditures (2025 - 2026) Analysis & Trends
RenovoRx has reported Capital Expenditures for 1 years, with the latest figure at $2000.0 in Q2 2025.
- Quarterly Capital Expenditures changed N/A year-over-year to $2000.0 in Q2 2025, while the trailing twelve-month figure through Mar 2026 was $2000.0 (changed N/A YoY) and the FY2025 annual result came in at $2000.0, down 83.33% from the prior year.
- Capital Expenditures was little changed at $2000.0 in Q2 2025 per RNXT's latest filing.
- Over five years, Capital Expenditures peaked at $2000.0 in Q2 2025 and troughed at $2000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.99 Bn | 132.14 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 86.80 Bn | 78.80 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 65.38 Bn | 60.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.70 Bn | 55.56 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 42.22 Bn | 37.12 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.45 Bn | 10.06 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.47 Bn | 26.31 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.21 Bn | 26.37 Bn | - | 251.02 Mn |
| 10 | RenovoRx | 61.49 Mn | 61.49 Mn | 766,000.00 | 200,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 134,000.00 |
| Jun 30, 2026 | 134,000.00 |
| Mar 31, 2026 | 66,000.00 |
| Mar 31, 2026 | 66,000.00 |
| Jun 30, 2025 | 2,000.00 |
| Jun 30, 2025 | 2,000.00 |